Richard Gorlick, M.D.
H. Grant Taylor, MD, W.W. Sutow, MD and Margaret P. Sullivan, MD, Distinguished Chair in Pediatrics
- Targeted Therapy
The research in my lab is focused on conducting translational studies aimed at improving outcomes for children, adolescents and young adults with osteosarcoma, which is the most common primary malignant bone tumor in this patient population. Utilizing genomic and proteomic approaches, our lab identifies novel targets in osteosarcoma ripe for therapeutic intervention with the goal of developing new immunotherapies to be assessed in pre-clinical studies and clinical trials.
The Gorlick Lab has been a member of the National Cancer Institute-funded Pediatric Preclinical Testing Program/Consortium since its inception and has assessed the efficacy of more than 80 novel anti-cancer agents in osteosarcoma patient-derived xenograft (PDX) models. Research in the Gorlick Lab has directly led to a number of osteosarcoma clinical trials within the Children’s Oncology Group.
Osteosarcoma is a genomically complex cancer and, to date, the cell of origin has not been determined. Our lab studies normal and malignant bone differentiation in an effort to identify the stage(s) of differentiation from which osteosarcoma develops. Knowledge of the cell of origin may allow for improved therapeutic targeting of the precursor osteosarcoma cells.